Combining the Anti-HER2 Antibody Trastuzumab with Taxanes in Breast Cancer: Results and Trial Considerations

Pegram, Mark D.; O'Callaghan, Carminda

doi:10.3816/cbc.2001.s.003

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2018

Publication Types

Select...

Article3

Book2

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The use of HER2 modulation in the adjuvant setting

Johnson

Esteva

2007

Curr Oncol Rep

View full text Add to dashboard Cite

Amplification of the her-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.

show abstract